DNA Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

$DNA part of a huge bear raid across many biotech stocks. Check out $GH $IBRX $TWST and many others today. Nothing news specific

$DNA Big pharma is showing up for the data layer. AbbVie, argenx, Lundbeck, Takeda in the antibody consortium. Lilly TuneLab already on the board. Autonomous labs + AI discovery. Watching the build. 🧬 #DNA

$DNA DNA is beginning to show the kind of momentum investors have been waiting for. Ginkgo Bioworks sits at the intersection of synthetic biology, AI and programmable biology, with a platform designed to make biological engineering faster, cheaper and more scalable. As sentiment improves and the stock begins climbing, the upside can become very powerful if commercial execution follows. DNA has been deeply discounted, so even a modest change in expectations could drive significant revaluation. For long-term believers in engineered biology, this could be the beginning of a much more exciting chapter.

$DNA up 30% this week and not a peep on the board today. that's a good sign. the last thing we need is retail piling in now.

$DNA Ginkgo is becoming the wet-lab layer for pharma AI. Lilly TuneLab + Novo autonomous lab + ARPA-H RNA manufacturing. Nebula still the core bet. 🚀 #DNA #SynBio #AIbiotech

$DNA Snake oil salesman Jason Kelly $85 million rev after he promised $1 billion 5 yrs ago?? Pure Crap

$DNA decided to take a small position here after many years to follow the stock. Lost a ton on AMRS but made up a little of those losses with $TWST DNA has been a disaster as a stock but the rise of AI and the new business model around automated labs may be the business model that finally works. Way too early to tell but I like the fact that NOVO and Lilly see something here. Clearly the market sees this going to zero and I get it given its past failures. But worth following now for the first time in years.

$DNA whether or not Ginkgo wins is besides the point in the near/medium. this has begun a re-rating because it is sitting smack dab in the middle of a revolution. Jason pivoted the company to get there a year before the world has begun to wake up. stop holding on to the past. this is a new day.

$DNA just opened its Boston autonomous lab to NSF’s $1.5B X-Labs. Remote cloud-lab time + protein testing for AI-designed proteins. Same stack: Nebula imaging with Araceli, antibody consortium with AbbVie/argenx/Lundbeck/Takeda, Lilly TuneLab, up to $17.5M ARPA-H RNA manufacturing, Novo RAC lab in Waltham. Biology, automated. 🚀🧬 #DNA #SynBio #Biotech

$DNA this thing has fucked me over so many times over the past 5 years… I finally throw in the towel and this piece of shit jumps

$DNA AI designs molecules → Ginkgo autonomous labs test them → Ginkgo generates standardized biological data → models improve → more experiments are sent back to Ginkgo. That feedback loop could be much more valuable than Ginkgo simply operating as a traditional contract-research company. If AI drug discovery explodes, high-quality experimental data becomes one of the scarce inputs, and Ginkgo is trying to position itself as that infrastructure/data layer.

$DNA is yet another example of a clean pullback entry (straight out of our free webinar on buying pullbacks) posted in Discord today by KevinP! .

$DNA AWS giving cloud credits to startups. Amazon doesn’t give them computing because it dislikes revenue. It wants developers building their businesses on AWS so that, when their usage becomes substantial, AWS is already their infrastructure. Ginkgo appears to be doing something similar with biology: Free/ subsidized experimental capacity → scientists adopt Ginkgo → protocols accumulate → platform improves → commercial usage grows → paid cloud-lab services / instruments / software / consumables.

$DNA This company literally has no business model. WTH is “ autonomous lab”? Short this to $0.

$DNA Making 88% in a month feels great. The next 6 months tend to be brutal. Just be aware of the risk.

$DNA Shyam Sankar CTO of $PLTR is the Chairman, not too shabby company to be around. approaching $1 Billion mkt cap.

$DNA I think the accumulation phase is nearly over. smart money will soon discover that we are sitting in the middle of a biological revolution.

$DNA high alert 🧨🧨 People saying going to moon this week. I say you’re nuts!!’ Yet very soon if you measure time same way. A solid catch. Keep fishing 🤙

$DNA seeing a lot of garbage posts I guess it’s related to stock price. Cause the company is building automated labs for players like Antropic and I don’t think they would have been chosen if their products were garbage 🚀.

$DNA In October 2021, Scorpion Capital released a report labeling Ginkgo a "colossal scam", alleging that most of its revenue came from related-party transactions and that many of its partnerships were overstated or misleading (they even mentioned some former employees’ testimonies, lol). When this news came out, Ginkgo’s stock fell 12%, and the DOJ launched an investigation. A month later, shareholders filed a lawsuit, accusing Ginkgo of inflating its revenue and hiding key risks. As you might know, Ginkgo has already agreed to settle, paying up to $17.75M to investors.